Overview

Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)

Status:
Unknown status
Trial end date:
2013-12-01
Target enrollment:
0
Participant gender:
All
Summary
Chronic fatigue syndrome (CFS) is a devastating and complex disorder. People with CFS experience overwhelming fatigue and a host of other symptoms that are not improved by bed rest. Interestingly, many of the symptoms experienced by people with CFS are identical to symptoms caused by long-term low-level exposure to mercury, which is called micromercurialism. This study will examine if the mercury binding substance IodoCarb(r) can improve the health of patients with CFS.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
PharmaLundensis AB
Treatments:
Charcoal
Criteria
Inclusion Criteria:

- Chronic fatigue syndrome

- 35-60 years old

- Male

- Female (not pregnant or breastfeeding, using adequate highly effective contraception
consistently and correctly or >1 year post-menopausal or surgically sterile).

Exclusion Criteria:

- Iodine allergy

- abnormal thyroid function or other thyroid disease such as goiter

- severely reduced kidney function (Cystatin C > 1.5 mg/L)

- alcohol/drug abuse

- severe depression

- severe fibromyalgia

- severe cardio-vascular disease

- other severe disease, according to the clinical investigator

- participation in another ongoing clinical trial

- participation in drug trial the preceding 3 months